

## Workshop

# “Diagnostics for reducing antimicrobial resistance (AMR)”

### Agenda

19, June 2017 • Hotel Renaissance Parnasse  
Rue du Parnasse 19 • 1050 Brussels • Belgium

#### Workshop objectives

- To consult with the relevant stakeholders on a potential Call for proposals under IMI2 addressing the topic ‘Diagnostics for reducing AMR’ that would aim at establishing a framework for value-based translation of innovative diagnostics into routine use to reduce AMR.
- To better understand the challenges and hurdles faced by diagnostic innovators for translation of early-stage products into validation, and value demonstration in primary and clinical healthcare practice.
- To obtain a better understanding of what evidence is needed from regulators, health technology assessment bodies and payers for implementation and adoption by healthcare systems.

**08:00 – 09:00** Registration and networking breakfast

**09:00 – 10:30** Session 1: Welcome & setting the scene

Session chair: *Angela Wittelsberger, Innovative Medicines Initiative*

9:00 – 9:05 **A word of welcome (video message)**

Pierre Meulien, Executive Director, Innovative Medicines Initiative

9:05 – 9:30 **The Innovative Medicines Initiative: building new models of collaborative research**

Angela Wittelsberger, Scientific Officer, Innovative Medicines Initiative

9:30 – 10:00 **Diagnostics to address antimicrobial resistance**

Mark Miller, Chief Medical Officer bioMérieux

10:00 – 10:30 **The World Health Organisation’s view on *in vitro* diagnostics for addressing antimicrobial resistance**

Francis Moussy, Lead for AMR Diagnostics, WHO

**The Wellcome Trust’s view on *in vitro* diagnostics for addressing antimicrobial resistance**

Timothy Jinks: Head - Wellcome Trust Drug Resistant Infections priority program

**The European Commission’s view on *in vitro* diagnostics for addressing antimicrobial resistance**

Arjon Van Hengel, DG Research & Innovation, European Commission

**10:30 – 11:00** Coffee break

**11.00– 12:00**      **Session 2: Presentation of preliminary plans for a topic under the Innovative Medicines Initiative “Diagnostics in AMR”**

Session chair: *Mark Miller (bioMérieux)*

**Implementation of diagnostics**, Volker Liebenberg (*Thermo Fisher*)  
**Where are the gaps towards a standardised care network?**, Philippe Cleuziat (*bioMérieux*)  
**Design of a clinical study to demonstrate the value of diagnostics**, Kieran Clarke (*Alere*)

**12.00– 12:30**      **Session 3: Round table “Value and challenges of diagnostics in clinical research”**

Panellists: Hermann Goossens (*University of Antwerp*), Valerie D’Acremont (*University Hospital of Lausanne*), Trinad Chakraborty (*Justus-Liebig University Giessen*), Rosanna Peeling (*London School of Hygiene and Tropical Medicine*)

Moderator: Timothy Jinks, Wellcome Trust

**12.30 – 14.00**      **Networking Lunch**

**14:00 – 15:30**      **Session 4: Flash presentations stakeholder perspectives**

*Stakeholder representatives should speak for maximum 5 min and are asked to address the following questions:*

- *What role should diagnostics play to address AMR from your perspective?*
- *What are the main gaps and challenges that should be addressed by a potential call topic under IMI to support the value of diagnostics?*

Academia – Till Bachmann (University of Edinburgh)

Small- and medium-sized enterprise – Holger Becker (microfluidic chipchop GmbH)

IVD Regulator – Isabelle Beredjian-Ding (Paul-Ehrlich-Institute)

Health Technology Assessment – Sheryl Warttig (National Institute for Health and Care Excellence)

Civil society – Joe Thomas (The Pew Charitable Trusts)  
– Khairunisa Suleiman (Consultant)

Clinical research – Jordi Vila (Hospital Clinic Barcelona)

MedTech industry – Yves Verboven (MedTech Europe)

Product Development Partnership – Jerome St. Denis (FIND)

*Spontaneous interventions*

**15:30 – 16:00**      **Open floor discussion  
Feed-back on the stakeholder perspectives**

Moderators: *Volker Liebenberg (Thermo Fisher) & Timothy Jinks (Wellcome Trust)*

**16:00 – 16:15**      **Summary, miscellaneous & next steps**

*Angela Wittelsberger, Innovative Medicines Initiative*